Hormonal
Combination therapy of sibutramine (10 mg/d) and topiramate (100 mg/d) produces clinically meaningful weight loss (mean 10.2 kg at 36 months) with a tolerable safety profile in real-world clinical settings.
For individuals with obesity who cannot access newer, expensive medications, the combination of sibutramine (10mg) and topiramate (100mg) offers a cost-effective, clinically significant weight loss solution (approx. 10kg over 3 years). It requires medical supervision to manage potential side effects like increased blood pressure or paresthesia, but offers a viable alternative for long-term management in resource-limited settings.
In a real-world setting, sibutramine and topiramate combination therapy was associated with clinically meaningful weight loss alongside a good tolerability profile.
Why this rating
Retrospective cohort study without a control group; real-world data but subject to confounding.
Source
Combination of sibutramine and topiramate for the treatment of obesity: the SIBAMATE retrospective cohort study
Cíntia Cercato et al. · Diabetology & Metabolic Syndrome · 2025
DOI 10.1186/s13098-025-01842-1
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →